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Thromboembolic risks associated with
paroxysmal and persistent atrial fibrillation
in Asian patients: a report from the Chinese
atrial fibrillation registry
Ying Wang1,2, Chang-Sheng Ma1* , Xin Du1*, Liu He1, Jie Li2, Guo-Hong Wang2, Dan Wen1, Jian-Zeng Dong1,
Jian-Hong Pan3 and Gregory Y. H. Lip4,5
Abstract
Background: Several studies have reported on atrial fibrillation (AF) outcomes, including thromboembolism in
patients with paroxysmal and non-paroxysmal AF; however the findings still remain controversial on whether risks
differ between these clinical subtypes and limited data are available in Asian cohorts.
Methods: We compared the risk of thromboembolism between paroxysmal and persistent AF patients, in a large
contemporary Chinese cohort study. A total of 8529 non-valvular atrial fibrillation (NVAF) patients from the Chinese
Atrial Fibrillation Registry (CAFR) study were enrolled. The study subjects were divided into two groups: paroxysmal
AF (PaAF, defined as AF lasting within 7 days, n = 4642) and persistent AF (PeAF, lasting over 7 days, n = 3887) groups.
Results: In non-anticoagulated patients, PeAF group demonstrated a higher risk of stroke, all-cause death, cardiac/
non-cardiac death and composition of stroke/ transient ischemic attack (TIA)/peripheral thromboembolism (PT)/all-
cause death, compared to the PaAF group. No significant difference was found in anticoagulated subjects. On
multivariate analysis in non-anticoagulated patients, age≥ 75 years (P = 0.046) and prior stroke/TIA/PT (P = 0.018) but
not AF type (P = 0.63) were significantly associated with the risk of stroke/TIA/PT events.
Conclusions: Stroke, all-cause death and cardiac/non-cardiac death in Chinese NVAF population was increased in non-
anticoagulated PeAF patients compared with PaAF group, but same between anticoagulated PeAF and PaAF patients.
After adjustment, AF type was not an independent predictor of thromboembolism in NVAF patients.
Clinical trial registration: Chinese Clinical Trial Registry ChiCTR-OCH-13003729. Registered 22 October 2013.
Keywords: Atrial fibrillation, Thromboembolism, Risk factors, Stroke, Outcome
Background
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia worldwide and is strongly associated
with the risk of stroke, thromboembolism and death [1].
The risks of thromboembolism are dependent on various
clinical risk factors for stroke [2]. Current guidelines rec-
ommend oral anticoagulation (OAC) in high risk patients,
irrespective of whether the AF pattern is paroxysmal or
persistent [3, 4]. Nevertheless, higher AF burden and a
more sustained AF pattern have been associated with a
greater risk of thromboembolism [5–13], although other
studies reported opposite findings [14–19]. The inconsist-
ency may be possibly due to different sample sizes enrolled
among previous studies, as well as smaller event numbers
due to OAC use. Also, limited data are available from
Asian population.
The Chinese Atrial Fibrillation Registry (CAFR) is a large
contemporary Chinese cohort study, documenting the clin-
ical epidemiology and outcomes in Chinese patients with
AF. In this report from CAFR, we compared the risk of
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thromboembolism between paroxysmal and persistent AF
patients.
Methods
The rationale and design of the CAFR study have been re-
ported previously [20, 21]. In brief, CAFR is a prospective,
multicenter, hospital-based ongoing registry conducted in
Beijing, China. Ethics approval was obtained from the institu-
tional review committee of Beijing Anzhen Hospital. Demo-
graphic data, comorbidities, treatments received and results
of laboratory examinations of each patient were recorded
after the patient signed the consent form. Every patient was
followed up by outpatient procedures or by telephone at the
time of 3months, 6months and every 6months thereafter.
Major events including ischemic stroke, systemic embolism
and bleeding were recorded during follow-up. After exclud-
ing those who received successful radiofrequency catheter
ablation therapy at baseline and during follow-up, data of
8529 NVAF patients collected between August 2011 and
June 2015 were used for the present analyses.
Paroxysmal AF was defined as with spontaneous
termination or with intervention within 7 days of onset,
although episodes may recur with variable frequency.
Persistent AF was defined as AF lasting>7 days. Because of
the sustained AF status of longstanding persistent AF and
permanent AF defined in AF guidelines, the two patterns
of AF were assigned to the persistent group in our study,
using a simplified scheme from Levy et al. [22]. AF type of
each patient was kept consistent with that of baseline re-
gardless of later changes during follow-up.
The clinical outcomes included the occurrence of fatal
and non-fatal ischemic stroke, transient ischemic attack
(TIA), other non-central nervous system (CNS) peripheral
thromboembolism (PT), intracranial hemorrhage, all-cause
death, cardiac death, non-cardiac death and composite out-
comes of stroke/TIA/ PT. Endpoint events were adjudicated
by neurologists according to the patients’medical records.
Baseline data of patients in different AF subtypes were
reported as mean ± standard deviation or median (25th,
75th percentiles) for continuous variables and frequen-
cies and percentages for categorical variables. Between-
group comparisons were performed using Wilcoxon
rank-sum tests for continuous variables and Pearson’s
chi-squared tests for categorical variables.
Kaplan–Meier curves were plotted for time to clinical
events in the two AF groups with or without warfarin or
other oral anticoagulants in order to avoid the confound-
ing effect of anticoagulation treatment on thromboembol-
ism events. Cumulative incidence rates were compared
with the log-rank test by groups. Multivariate Cox propor-
tional hazards regression model was used to analyze the
independent risk factors for stroke/TIA/PT [23, 24] and
to assess the association between AF type and stroke risk,
adjusted for AF types and components of CHA2DS2-VASc
score: congestive heart failure, hypertension, age ≥ 75
years, age 65-74 years, diabetes mellitus, previous history
of stroke/TIA/PT, vascular diseases and female gender.
The proportional hazard assumption was assessed using
supremum test. P value < 0.05 was regarded as statistically
significant. All tests of significance were two-sided. All
statistical analysis was made using SAS version 9.4 (SAS
Institute, Cary, NC, USA).
Results
There were 4642 patients with PaAF (54.43%) and 3887
patients with PeAF (46.88%) included for the current ana-
lysis (Table 1). Compared with PeAF patients, PaAF pa-
tients were younger, had smaller left atria (LA) diameter,
and had higher creatinine clearance rate (P<0.001). PeAF
group had a longer history of AF and higher CHADS2 and
CHA2DS2-VASc scores. At baseline, PeAF patients had
greater prevalence of prior history with hypertension,
stroke/TIA/PT, heart failure, diabetes, myocardial infarc-
tion and peripheral artery diseases (P<0.001), with no dif-
ference in history of other coronary diseases and thyroid
diseases. More patients with left ventricular ejection frac-
tion (LVEF) less than 40% were in PeAF group compared
with PaAF group (P<0.001). Significant higher proportions
of patients with age ≥ 75 years, female sex, CHADS 2 and
CHA2DS2-VASc scores ≥2 were observed.
Medical therapy at baseline in the two patient groups
are listed in Table 1. Approximately 30% of patients with
paroxysmal AF and 46.5% of patients with persistent AF
were on warfarin or new oral anticoagulants (NOACs).
Patients of PeAF group were more likely to be taking rate
control medicines, including beta-blockers and digoxin,
while PaAF group were more frequently treated with ami-
odarone. More patients in PeAF group were taking angio-
tensin converting enzyme inhibitors/angiotensin receptor
blockers (ACEI/ARBs) drugs in comparison to those in
PaAF group, possibly as a consequence of higher preva-
lence of congestive heart failure in PeAF group.
Incidence rates of thromboembolic events according to
AF types were shown in Table 2, stratified by application
of oral anticoagulation drugs. For AF patients not on anti-
coagulant therapy, the incidences of stroke/TIA/PT were
1.9 vs. 1.3 per 100 patient years for PeAF and PaAF, re-
spectively (P<0.003). Likewise, risk of all-cause death and
cardiac/non-cardiac death was higher in PeAF patients.
Kaplan-Meier curves for PeAF vs. PaAF patients with or
without OAC for outcomes of stoke/TIA/PT, all-cause
death, cardiac death, non-cardiac death, are shown in
Fig. 1. For patients not on OAC, PaAF group exhibited
significantly lower HRs than PeAF group in risk of stroke/
TIA/PT (P < 0.003), all cause death (P < 0.0001), cardiac
death (P < 0.0001) and non-cardiac death (P < 0.0001). For
patients on OAC, clinical outcomes aforementioned were
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Table 1 Characteristics of patients with paroxysmal and persistent AF at study entry
Characteristics PaAF (n = 4642) PeAF (n = 3887) P value
Age (y, mean ± SD)a 66.8 ± 12.12 69.1 ± 11.23 0.000
Age group
65–74 years, n (%)a 1294 (49.83%) 1078 (44.20%) < 0.001
≥ 75 years, n (%) 1303 (50.17%) 1361 (55.80%)
Gender, female, n(%) 2007 (43.24%) 1542 (39.67%) < 0.001
BMI (kg/m2, mean ± SD) 25.1 ± 3.69 25.4 ± 3.69 < 0.001
SBP (mmHg, mean ± SD) 129.2 ± 17.17 128.6 ± 17.76 0.114
DBP (mmHg, mean ± SD) 76.9 ± 10.67 78.4 ± 11.38 0.000
LA diameter (mm, mean ± SD) 39.1 ± 6.72 44.9 ± 7.09 0.000
Duration of AF history (y, mean ± SD) 4.6 ± 6.19 6.8 ± 7.40 0.000
Ccr (ml/min, mean ± SD) 78.0 ± 33.13 74.3 ± 33.65 < 0.001
CHADS 2 score (mean ± SD) 1.7 ± 1.37 2.1 ± 1.46 0.000
CHADS 2 score n(%)
0 909 (19.58%) 503 (12.94%) < 0.001
1 1514 (32.62%) 1017 (26.16%)
≥ 2 2219 (47.80%) 2367 (60.90%)
CHA2DS2-VASC score (mean ± SD) 2.9 ± 1.89 3.3 ± 1.96 0.000
CHA2DS2-VASC score n(%)
0 447 (9.63%) 255 (6.56%) < 0.001
1 764 (16.46%) 515 (13.25%)
≥ 2 3431 (73.91%) 3117 (80.19%)
LVEF(%, mean ± SD) 63.0 ± 9.31 58.9 ± 11.29 0.000
Comorbidities n(%)
Hypertension 3156 (68.11%) 2729 (70.35%) 0.025
Congestive heart failure 296 (6.38%) 783 (20.16%) < 0.001
LVEF
≥ 40% 2993 (97.27%) 2552 (92.67%) < 0.001
0–40% 84 (2.73%) 202 (7.33%)
Diabetes 1137 (24.49%) 1071 (27.55%) 0.001
Prior stroke/TIA/PT 819 (17.64%) 885 (22.78%) < 0.001
Prior myocardial infarction 262 (5.65%) 259 (6.67%) 0.049
Other coronary artery diseases 815 (17.57%) 647 (16.66%) 0.269
Peripheral artery diseases 34 (1.75%) 44 (3.18%) 0.007
Thyroid diseases 153 (7.75%) 100 (7.06%) 0.452
Baseline medication n(%)
Aspirin 2220 (47.96%) 1662 (42.86%) < 0.001
Warfarin/NOAC 1363 (29.36%) 1808 (46.51%) < 0.001
β-blockers 2493 (53.71%) 2291 (58.94%) < 0.001
Digoxin 387 (8.34%) 1374 (16.11%) < 0.001
Amiodarone 502 (10.81%) 130 (3.34%) < 0.001
Statins 1754 (37.89%) 1551 (39.98%) 0.049
ACEI/ARBs 1705 (36.73%) 1755 (45.15%) < 0.001
AF indicates atrial fibrillation, PaAF paroxysmal atrial fibrillation, PeAF persistent atrial fibrillation, SD standard deviation, TIA transient ischemic attack, PT
peripheral thromboembolism, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LA left atria, Ccr creatinine clearance rate,
LVEF left ventricular ejection fraction, NOAC new oral anticoagulantion, PT peripheral thromboembolism, ACEI/ARB angiotensin converting enzyme
inhibitors/angiotensin receptor blockers, CHADS2 congestive heart failure, hypertension, age 75 years or more, diabetes mellitus and stroke, and
CHA2DS2-VASc congestive heart failure, hypertension, age 75 years or more, diabetes mellitus, stroke, vascular disease, age 65–74 years and sex category
aData given as n (%) or mean ± SD
Wang et al. BMC Cardiovascular Disorders          (2019) 19:283 Page 3 of 9
similar in PaAF as in PeAF patients (P = 0.955, P = 0.327,
P = 0.237, P = 0.599, respectively).
In patients not on anticoagulation, univariate analysis
demonstrates that AF type and components of CHA2DS2-
VASc score except for the history of diabetes and female
sex were associated with stroke/TIA/PT events (Table 3).
On multivariate Cox proportional hazards regression
models, age ≥ 75 years [HR 2.10 (1.01–4.360), P = 0.046)]
and prior stroke/TIA/PT [HR 1.86 (1.11–3.11), P = 0.018)]
but not AF type [HR 1.13 (0.69–1.86), P = 0.63] were inde-
pendently associated with the risk of stroke/TIA/PT events.
Discussion
In this report from CAFR, our data collected from 8529
NVAF patients demonstrated that in non--anticoagulated
patients, risk of thromboembolic events was higher in
PeAF than PaAF before adjusting confounders. However,
this difference became not significant after adjusting age,
sex, history of stroke, hypertension and vascular diseases.
In contrast, in anticoagulated patients, thromboembolic
risk did not differ between PaAF and PeAF before and
after adjusting possible confounders.
This is one of the first comparisons of thromboembolic
outcomes in different NVAF patterns in large Chinese
population. As patients receiving catheter ablation treat-
ment had a low incidence of stroke [25], we excluded those
who received catheter ablation and with no AF recurrence,
to avoid the dilution effect of low-risk patients. Our results
strengthen the recommendation of current guidelines on
stroke prevention for NVAF patients, suggesting choosing
Table 2 Thromboembolic outcomes in different groups of atrial fibrillation type stratified by anticoagulant drugs during follow-up
Thromboembolic
outcomes
With warfarin/NOAC HR(95%CI) P value a Without warfarin/NOAC HR (95%CI) P valuea
Total
events/n
Incidence
rates/100 pt.ayrs
Total events/n Incidence
rates/100 pt.ayrs
Stroke /TIA/PT
PeAF 51/1804 1.2 0.988 0.955 100/2078 1.9 1.521 0.003
PaAF 37/1359 1.3 (0.647–1.509) 99/3276 1.3 (1.152–2.008)
Stroke
PeAF 41/1805 1.0 1.014 0.953 72/2078 77/3276 1.4 1.414 0.003
PaAF 29/1360 1.0 (0.633–1.630) 1.0 (1.025–1.950)
TIA
PeAF 11/1807 0.3 0.988 0.980 33/2079 0.6 2.301 0.003
PaAF 8/1362 0.3 (0.397–2.457) 21/3279 0.3 (1.331–3.977)
PT
PeAF 2/1808 0.0 0.470 0.408 8/3279 0.1 0.919 0.882
PaAF 3/1363 0.1 (0.078–2.814) 5/2079 0.1 (0.300–2.810)
Intracranial hemorrhage
PeAF 9/1808 0.2 1.806 0.875 5/2079 0.1 1.059 0.923
PaAF 6/1363 0.2 (0.386–3.054) 7/3278 0.1 (0.336–3.337)
All-cause death
PeAF 57/1806 1.4 1.242 0.327 201/2068 4.0 3.028 < 0.0001
PaAF 33/1361 1.2 (0.805–1.916) 104/3271 1.3 (2.389–3.836)
Cardiac death
PeAF 21/1807 0.5 1.603 0.237 101/2073 1.9 4.314 < 0.0001
PaAF 10/1362 0.3 (0.734–3.503) 36/3278 0.5 (2.949–6.312)
Non-cardiac death
PeAF 30/1808 0.7 1.17 0.599 68/2078 47/3275 1.3 2.18 < 0.0001
PaAF 18/1362 0.6 (0.652–2.099) 0.6 (1.503–3.162)
Stroke /TIA/PT/all-cause death
PeAF 103/1802 2.6 1.119 0.478 285/2067191/3268 5.9 2.352 < 0.0001
PaAF 66/1357 2.4 (0.820–1.527) 2.5 (1.958–2.825)
NOAC indicates new oral anticoagulation, HR hazard ratio, CI confidence interval, TIA transient ischemic attack, PT peripheral thromboembolism, PaAF paroxysmal
atrial fibrillation, and PeAF persistent atrial fibrillation
aIncidence rates were compared by Cox proportional hazards regression models, stratified by anticoagulant drugs
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Fig. 1 Kaplan-Meier curves for occurrence of outcomes in PeAF vs. PaAF patients with or without OAC. a, b Stroke/TIA/PT; c, d all-cause death; e,
f cardiac death; g, h non-cardiac death
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anticoagulation treatment should not base on the pat-
tern of AF.
Current guidelines recommend that the pattern of AF
should not be taken into account when assessing the stroke
risk and deciding the choice for thromboembolism prophy-
laxis treatment in patients with AF [3, 4], despite that the
burden of AF is higher in PeAF patients than that in PaAF
patients. Whether AF pattern is associated with stroke risk
has aroused wide concern over the recent years.
Clinical trial cohorts have reported contradictory find-
ings. A sub-analysis of the Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico-Atrial Fibrilla-
tion (GISSI-AF) trial [14] reported a similar rate of
thromboembolic events in patients with PeAF and PaAF,
with a much lower incidence among the overall popula-
tion (0.97%) compared with our findings. In the Random-
ized Evaluation of Long-Term Anticoagulation Therapy
(RE-LY) trial [17], the overall risk of stroke or systemic
embolism in patients with paroxysmal, persistent, and per-
manent AF were similar, with rates of 1.32, 1.55, and
1.49% per year, respectively. In contrast, other trials have
reported different results. In the Rivaroxaban Once-daily,
Oral, Direct Factor Xa Inhibition Compared with Vitamin
K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation (ROCKET-AF) study [13],
patients with PeAF had higher adjusted rates of stroke or
systemic embolism (2.18 vs. 1.73% per year, P = 0.048) and
all-cause mortality (4.78 vs. 3.52, P = 0.006) compared
with patients with PaAF. The same was found in SPOR-
TIF (Stroke Prevention Using an Oral Thrombin Inhibitor
in Atrial Fibrillation) III and V trials [11]. AF pattern was
found to be an independent predictor of stroke in the sub-
analysis of AVERROES (Apixaban Versus ASA to Prevent
Stroke In AF Patients Who Have Failed or Are Unsuitable
for Vitamin K Antagonist Treatment) and ACTIVE A (the
Atrial Fibrillation Clopidogrel Trial With Irbesartan for
Prevention of Vascular Events) trials [7], which only se-
lected aspirin-treated NVAF patients.
Observational cohorts have also reported contradictory
findings. The incidence of ischemic stroke adjusted by war-
farin and other risk factors was similar in PaAF as in PeAF
(2.6 vs. 2.9 per 100 patient years) from the Stockholm Co-
hort of Atrial Fibrillation [15]. In an Asian cohort, the crude
event rate was 2-fold higher among the permanent NVAF
patients (2.29%) than paroxysmal (1.16%) or persistent
(1.20%) AF patients (P = 0.001), while after adjustment for
warfarin use and risk factors, the hazard ratio for thrombo-
embolism did not differ between paroxysmal and perman-
ent groups [16]. In a Japanese study, Takabayashi et al.
observed PaAF was independently associated with lower
incidence of stroke/systemic embolism than sustained AF
in patients with or without anticoagulants [8].
One of the possible reasons for the inconsistent results
may be due to the use of antithrombotic therapy for pre-
venting stroke, which will limit the outcome events and
therefore, reduce the power to detect the difference of
stroke incidence across AF patterns. Inconsistent anticoa-
gulation strategy by design, imbalances of anticoagulant in-
tensity and differences in the use of OAC rates may act as
confounders. Different anti-platelet and/or anticoagulant
therapy including aspirin, warfarin and new oral anticoagu-
lants were used in various studies, with different efficacy in
preventing thromboembolism. For example, the ACTIVE A
and AVERROES trials [7] observed aspirin-treated NVAF
patients and concluded different rates of ischemic stroke
were 2.1, 3.0 and 4.2% per year for paroxysmal, persistent,
and permanent AF respectively. In the ARISTOTLE (Apix-
aban for Reduction in Stroke and Other Thrombo-embolic
Events in Atrial Fibrillation) trial [12], in which all of the
patients were treated with warfarin or NOAC, the rate of
stroke or systemic embolism was significantly higher in pa-
tients with persistent or permanent AF than paroxysmal
group (1.52 vs. 0.98%, adjusted P = 0.015).
Of note, few studies observed thromboembolism inci-
dence according to the stratified application of antico-
agulants in different AF types. In our cohort, risk of
Table 3 Univariate and multivariate analysis: stroke/TIA/PT risk factors in NVAF patients not on anticoagulants
Risk factors Univariate Multivariate
HR (95%CI) P value HR (95%CI) P value
PeAF vs PaAF 1.52 (1.15–2.00) 0.0031 1.13 (0.69–1.86) 0.63
Congestive heart failure 1.54 (1.09–2.17) 0.014 1.00 (0.55–1.82) 0.99
Age (≥75ys) 3.56 (2.38–5.35) < 0.0001 2.10 (1.01–4.36) 0.046
Age (65-74ys) 2.06 (1.30–3.25) 0.002 1.38 (0.62–3.08) 0.44
Hypertension 1.84 (1.30–2.61) 0.0005 1.39 (0.71–2.74) 0.34
Diabetes 1.00 (0.73–1.39) 0.996 0.82 (0.48–1.39) 0.46
Prior stroke/TIA/PT 2.51 (1.87–3.37) < 0.0001 1.86 (1.11–3.11) 0.018
Female 1.15 (0.87–1.53) 0.31 1.44 (0.89–2.34) 0.14
Vascular diseases 2.43 (1.42–4.16) 0.001 1.54 (0.85–2.78) 0.16
TIA indicates transient ischemic attack, PT peripheral thromboembolism, NVAF non-valvular atrial fibrillation, HR hazard ratio, and CI confidence interval
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thromboembolic events were compared between PaAF
and PeAF patients based on OAC therapy. Univariate
and multivariate analysis of Cox proportional hazards
regression models were performed in the absence of
OAC therapy to evaluate the predictive value of AF
types more accurately. For non-anticoagulated patients,
PeAF group demonstrated a trend towards worse out-
comes, with higher incidences of stroke/TIA/PT, all-
cause death and cardiac/non-cardiac death than PaAF
patients. In OAC users, risk of outcomes was compar-
able between PaAF and PeAF groups. Age ≥ 75 yrs. and
prior history of stroke/TIA/PT were independent pre-
dictors for thromboembolism, which was consistent
with most of the prior studies. The Fushimi Atrial Fib-
rillation Registry (The Registry Study of Atrial Fibrilla-
tion Patients in Fushimi-ku) [8] reported a lower risk of
stroke/systemic embolism in PaAF patients both in
non-OAC/OAC users and confirmed PaAF was an in-
dependent predictor of lower stroke/systemic embolism
risk. However, our data did not find the difference, al-
though our sample size was larger, and patients in our
study had higher proportion of PaAF patients and
slightly lower CHADS2 /CHA2DS2-VASC score.
Other reasons may possibly explain the conflicting re-
sults in different studies. For example, different risk
levels of the study population are relevant. The present
study showed a majority of baseline variables were evi-
dently different between PeAF and PaAF patients, with
higher risk and more underlying comorbidities in PeAF
type. PaAF group had a lower CHADS2 (PaAF vs. PeAF:
1.7 vs.2.1, P = 0.000) and CHA2DS2-VASc score (PaAF
vs. PeAF 2.9 vs. 3.3, P = 0.000), which was similar with
ACTIVE-A and AVERROES [7], but lower than the re-
sults from ROCKET-AF [13] trial (mean CHADS2 score
3.5 for both types). Our data indicated significant varia-
tions of stoke risk factors between the two types. In the
presence of known risk factors involved in CHA2DS2-
VASc score, progression from sinus rhythm to PaAF or
more sustained forms is frequently seen along with atrial
electrical and structural remodeling. AF types reflect dif-
ferent states in the process of AF progression and may
be the consequence of interaction between CHA2DS2-
VASC components rather than the risk factor of stroke.
Different proportion of PaAF patients was included in
previous studies. The proportion of PaAF (54.4%) among
8529 NVAF patients in our study was similar with that
of the Loire Valley Atrial Fibrillation Project (58.4%)
[18], but higher than most of other studies which re-
cruited PaAF patients less than 50%, such as ACTIVE A
and AVERROES trials (24%) [7], ROCKET-AF trial
(17.6%) [13], ACTIVE W(Atrial Fibrillation Clopidogrel
Trial With Irbesartan for Prevention of Vascular Events)
Substudy (17.9%) [19], J-RHYTHM Registry (38.3%) [16]
and Fushimi study (48,1%) [8]. In GISSI-AF trial [14],
higher proportion of PaAF patients (62.5%), lower
CHADS2 score (1.41 ± 0.84) and lower incidence of
thromboembolic events (0.97%) were observed com-
pared with our study. PaAF represented the early stage
of AF progression, with lower AF burden than PeAF.
The duration and frequency of AF episodes may have
contributed to the conflicting results from prior reports.
Definitions of stroke were also different in previous tri-
als, such as ischemic stroke (i.e. cardioembolic, athero-
thrombotic, or lacunar infarction) or hemorrhagic stroke,
or both types. Different criteria of event ascertainment
may lead to discrepancy in rate of stroke and systemic em-
bolism. In the ARISTOTLE, Stockholm studies and Fush-
imi Registry [8, 12, 15], stroke endpoints were defined as a
composite of ischemic and hemorrhagic stroke, while in
our study and some others [14, 26], only ischemic stroke
associated with AF was designed as clinical endpoints that
may limit the number of events.
The event rates in our study were lower compared to
that reported in other studies, despite the CHADS2 and
CHA2DS2-VASc scores were similar [8]. The lower inci-
dence of thromboembolic events may be attributed to
our study being a cohort reflecting current practice, with
blood pressure, cholesterol and other risk factors well
controlled compared to prior studies. In patients with
AF and hypertension, having any elevated BP measure-
ments was independently associated with a higher risk of
stroke or systemic embolism [27]. This is supported by
the post-hoc analysis of GISSI-AF trial [14], where the
event rate was only 0.97% per year in patients without
anticoagulants, even lower than our study. We used an
independent endpoint adjudication committee to valid-
ate stroke event, which is not the usual way in observa-
tional studies and excluded about one quarter of stroke
events which is self-reported by patients while turned
out not to be a true event. Multiple studies have shown
a progressive decline in the incidence of thromboembol-
ism in non-anticoagulated patients identified with NVAF
over the past several decades, which is evident in the
present study that reports crude incident rates of ~ 2/
100 patient years for thromboembolism. The progressive
decline in thromboembolism of non-anticoagulated
NVAF patients is undoubtedly multifactorial and may be
secondary to improved treatment of morbidities and also
by early identification of lower risk NVAF patients.
We stratified OAC use in different groups and adjusted
several risk factors of thromboemblism. Some residual
confoundings might still remain even after multivariate
adjustment, especially factors like obesity, sleep apnea and
smoking etc. Previous studies consistently indicated AF
burden detected by implanted devices was associated with
an increased risk of ischemic stroke [28, 29], but it is not
possible for us to further stratify the PaAF patients into
different levels of AF burden to investigate the differences
Wang et al. BMC Cardiovascular Disorders          (2019) 19:283 Page 7 of 9
in risk. Future investigations are necessary to indentify the
correlation between AF pattern, AF burden and thrombo-
embolic events.
Conclusions
Overall, in our large cohort of Chinese NVAF popula-
tion, stroke, all-cause death and cardiac/non-cardiac
death was higher in non-anticoagulated PeAF patients
compared with PaAF group, but same between anticoa-
gulated PeAF and PaAF patients. After adjustment, AF
type was not an independent predictor of thrombo-
embolism in NVAF patients.
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